Barbiturates Interactions

CNS depressants; refer to WARNINGS section for detailed guidance.

Source: NLP:amitriptyline hydrochloride

CNS-depressant action of clonazepam may be potentiated by barbiturates, increasing risk of sedation and respiratory depression.

Source: NLP:clonazepam

Actions of benzodiazepines may be potentiated by barbiturates.

Source: NLP:clorazepate dipotassium

Diazepam injection has produced hypotension or muscular weakness when used with barbiturates. May potentiate diazepam action.

Source: NLP:diazepam

Barbiturate administration causes folate deficiency through increased loss or metabolic interference.

Source: NLP:folic acid

Produces increased CNS-depressant effects including respiratory depression and sedation.

Source: NLP:lorazepam

May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabolism of contraceptive steroids.

Source: NLP:norethindrone

Promethazine increases sedative action; dose of barbiturates should be reduced by at least one-half.

Source: NLP:promethazine hydrochloride

Promethazine may increase, prolong, or intensify sedative action. Dose should be reduced by at least one-half when given concomitantly.

Source: NLP:promethazine hydrochloride and dextromethorphan hydrobromide

May increase anesthetic/sedative effects and cardiorespiratory depression; can result in pronounced decreases in blood pressure and cardiac output.

Source: NLP:propofol

Produces additive CNS-depressant effects when co-administered with temazepam.

Source: NLP:temazepam

Potentiation of orthostatic hypotension may occur when given concurrently with hydrochlorothiazide.

Source: NLP:amiloride hydrochloride and hydrochlorothiazide

Possibility of additive or potentiating effect with CNS depressants.

Source: NLP:apraclonidine

Atropine may potentiate the effect of barbiturates. Barbiturates should be used cautiously in treating convulsions from atropine exposure.

Source: NLP:atropine

Atropine may potentiate the effect of barbiturates. Barbiturates should be used cautiously in treating convulsions from atropine exposure.

Source: NLP:atropine sulfate injection usp, 0.5 mg/0.7 ml

Hepatic enzyme induction may enhance corticosteroid metabolism, requiring increased corticosteroid dosage.

Source: NLP:betamethasone sodium phosphate and betamethasone acetate

Possibility of additive or potentiating CNS depressant effect with brimonidine.

Source: NLP:brimonidine

CNS depressant with potential for additive or potentiating effect when used with brimonidine tartrate ophthalmic solution.

Source: NLP:brimonidine tartrate

CNS depressant with possibility of additive or potentiating effect on central nervous system depression.

Source: NLP:brimonidine tartrate and timolol maleate

Barbiturates may result in additive or potentiating CNS depressant effects with YUVEZZI.

Source: NLP:carbachol and brimonidine tartrate

Potentiation of orthostatic hypotension may occur when barbiturates are given concurrently with chlorothiazide.

Source: NLP:chlorothiazide

Potentiation of orthostatic hypotension may occur when barbiturates are given concurrently with chlorothiazide sodium.

Source: NLP:chlorothiazide sodium

Barbiturates decrease plasma levels of clomipramine.

Source: NLP:clomipramine hydrochloride

Barbiturates may decrease plasma levels of clomipramine; dosage adjustment may be needed.

Source: NLP:clomipramine hydrochloride capsules

Clonidine may potentiate the CNS-depressive effects of barbiturates.

Source: NLP:clonidine

Clonidine may potentiate the CNS-depressive effects of barbiturates.

Source: NLP:clonidine hydrochloride

Clonidine may potentiate CNS-depressive effects of barbiturates.

Source: NLP:clonidine transdermal system

Cyclobenzaprine may enhance the effects of barbiturates and CNS depression.

Source: NLP:cyclobenzaprine

Cyclobenzaprine may enhance CNS depressant effects of barbiturates.

Source: NLP:cyclobenzaprine hydrochloride

Barbiturates induce CYP3A4 enzyme activity, enhancing corticosteroid metabolism and requiring dose increases.

Source: NLP:depo-medrol, lidocaine, isopropyl alcohol

Similar association with reduced efficacy and breakthrough bleeding suggested, though less marked than with rifampin.

Source: NLP:desogestrel and ethinyl estradiol and ethinyl estradiol

CYP 3A4 inducers may enhance metabolism of dexamethasone, requiring dosage increase.

Source: NLP:dexamethasone

Barbiturates induce CYP 3A4 enzyme activity, enhancing dexamethasone metabolism and requiring dosage increase.

Source: NLP:dexamethasone 1.5 mg

Barbiturates induce CYP 3A4 and enhance dexamethasone metabolism, requiring dosage increase.

Source: NLP:dexamethasone intensol

May potentiate CNS depressant effects of diphenoxylate hydrochloride and atropine sulfate. Monitor for CNS adverse reactions.

Source: NLP:diphenoxylate hydrochloride and atropine sulfate

Barbiturates shorten the half-life of doxycycline, thereby lowering doxycycline concentration in the body.

Source: NLP:doxycycline

Barbiturates decrease the half-life of doxycycline.

Source: NLP:doxycycline hyclate

Additive or potentiating CNS depressant effects; droperidol dose should be reduced when used concomitantly.

Source: NLP:droperidol

Induce CYP3A4 enzyme, may decrease effectiveness of COCs or increase breakthrough bleeding.

Source: NLP:drospirenone and ethinyl estradiol

May decrease the effectiveness of hormonal contraceptives or increase breakthrough bleeding through CYP3A4 enzyme induction.

Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium

Enzyme inducers that may decrease effectiveness of COCs or increase breakthrough bleeding. Use back-up contraception.

Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium

Potent CYP3A inducers expected to decrease estazolam concentrations; also produce CNS depression that may potentiate benzodiazepine action.

Source: NLP:estazolam

Similar association with reduced efficacy, though less marked than rifampin.

Source: NLP:ethynodiol diacetate and ethinyl estradiol

May decrease plasma concentrations of etonogestrel and diminish contraceptive effectiveness or increase breakthrough bleeding.

Source: NLP:etonogestrel

CYP3A4 enzyme inducer that may decrease plasma concentrations of etonogestrel and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Source: NLP:etonogestrel and ethinyl estradiol

Increased metabolic clearance of fludrocortisone acetate due to hepatic enzyme induction. May require increased steroid dosage.

Source: NLP:fludrocortisone acetate

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Source: NLP:glimepiride

Barbiturates usually depress griseofulvin activity by decreasing plasma levels, requiring dosage adjustment of griseofulvin.

Source: NLP:griseofulvin

Potentiation of orthostatic hypotension may occur.

Source: NLP:hydrochlorothiazide

Barbiturates induce cytochrome P450 3A4 enzyme activity, enhancing corticosteroid metabolism and requiring increased corticosteroid dosage.

Source: NLP:hydrocortisone sodium succinate

Hepatic enzyme inducers that decrease imipramine plasma concentration. Dose adjustment of imipramine may be necessary.

Source: NLP:imipramine hydrochloride

CYP3A4 inducers that decrease ivabradine plasma concentrations. Avoid concomitant use.

Source: NLP:ivabradine

Barbiturates induce CYP3A4 and may decrease plasma concentrations of COCs, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Source: NLP:levonorgestrel and ethinyl estradiol and ferrous bisglycinate

Barbiturates induce CYP3A4 enzymes, potentially decreasing contraceptive effectiveness and increasing breakthrough bleeding.

Source: NLP:norethindrone and ethinyl estradiol and ferrous fumarate

Enzyme inducers that may decrease plasma concentrations of contraceptive hormones and reduce effectiveness of hormonal contraceptives or increase breakthrough bleeding.

Source: NLP:levonorgestrel / ethinyl estradiol and ethinyl estradiol

Lofexidine may potentiate CNS depressant effects of barbiturates.

Source: NLP:lofexidine hydrochloride

Hepatic enzyme inducers may increase corticosteroid clearance.

Source: NLP:ammonia, lidocaine hydrochloride, triamcinolone acetonide, povidone-iodine

May decrease effectiveness of medroxyprogesterone acetate through enzyme induction. Counsel use of back-up or alternative contraception.

Source: NLP:medroxyprogesterone acetate

Barbiturates induce cytochrome P450 3A4 and may enhance corticosteroid metabolism, requiring dosage increase.

Source: NLP:methylprednisolone acetate

Hepatic enzyme inducers that enhance corticosteroid metabolism and may require increased corticosteroid dosage.

Source: NLP:methylprednisolone sodium succinate

Hypotensive effects may be potentiated by volume contraction associated with metolazone therapy.

Source: NLP:metolazone

Additive drowsiness and CNS depression reported with concurrent use. Caution advised.

Source: NLP:nabilone

Enzyme inducers that may decrease plasma concentrations of CHCs and potentially diminish effectiveness or increase breakthrough bleeding.

Source: NLP:norelgestromin and ethinyl estradiol

CYP3A4 inducer that may decrease the effectiveness of COCs or increase breakthrough bleeding.

Source: NLP:norethindrone acetate and ethinyl estradiol, and ferrous fumarate

Enzyme inducers that may decrease plasma concentrations of norethindrone and ethinyl estradiol, potentially diminishing contraceptive effectiveness or increasing breakthrough bleeding.

Source: NLP:norethindrone and ethinyl estradiol

CYP3A4 enzyme inducers that may decrease plasma concentrations of COCs and potentially diminish contraceptive effectiveness or increase breakthrough bleeding.

Source: NLP:norgestimate and ethinyl estradiol

CNS depressants that may increase CNS depression when used with FYCOMPA. Patients should limit activity until experienced with concomitant use.

Source: NLP:perampanel

Concomitant use with CNS depressants may potentiate CNS depression such as dizziness or cognitive adverse reactions.

Source: NLP:phentermine and topiramate extended-release

Barbiturates induce hepatic microsomal enzyme activity and enhance metabolism of prednisolone, requiring increased prednisolone dosage.

Source: NLP:prednisolone sodium phosphate

CYP 3A4 enzyme inducers enhance metabolism of corticosteroids, requiring increased prednisone dosage.

Source: NLP:prednisone

Promethazine may increase, prolong, or intensify sedative action; dose of barbiturates should be reduced by at least one-half.

Source: NLP:promethazine hydrochloride and phenylephrine hydrochloride

Protriptyline may enhance the effects of barbiturates.

Source: NLP:protriptyline hydrochloride

CYP3A4 and CYP2C8 inducers. Repaglinide dose increase and increased glucose monitoring may be required during concomitant use.

Source: NLP:repaglinide

Renal clearance of acidic drugs like barbiturates may be increased due to alkalinizing action of lactate.

Source: NLP:sodium chloride, sodium lactate, potassium chloride, calcium chloride

Potentiation of orthostatic hypotension may occur.

Source: NLP:spironolactone

Potentiation of orthostatic hypotension may occur.

Source: NLP:spironolactone and hydrochlorothiazide

Trazodone may enhance effects of barbiturates and other CNS depressants.

Source: NLP:trazodone hydrochloride

Hepatic enzyme inducers may increase corticosteroid clearance, reducing their effect.

Source: NLP:triamcinolone acetonide

CYP 3A4 inducers enhance metabolism of corticosteroids and may require dosage increase.

Source: NLP:triamcinolone acetonide extended-release injectable suspension

Sevoflurane administration is compatible with barbiturates and other commonly used intravenous anesthetics.

Source: NLP:sevoflurane